Risk factors during pregnancy and birth-related complications in HIV-positive versus HIV-negative women in Denmark, 2002-2014.
Adult
Case-Control Studies
Cesarean Section
/ statistics & numerical data
Denmark
/ epidemiology
Female
Fetal Diseases
/ epidemiology
Gestational Age
HIV Infections
/ complications
Humans
Maternal Age
Multivariate Analysis
Pregnancy
Pregnancy Outcome
/ epidemiology
Retrospective Studies
Risk Factors
birth complications
caesarean section
intrauterine growth retardation
pregnancy
preterm delivery
risk factors
women living with HIV
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
accepted:
31
07
2019
pubmed:
12
10
2019
medline:
2
6
2021
entrez:
12
10
2019
Statut:
ppublish
Résumé
We aimed to compare risk factors for adverse pregnancy outcomes in women living with HIV (WLWH) with those in women of the general population (WGP) in Denmark. Further, we estimated risk of pregnancy- or birth-related complications. A retrospective cohort study including all WLWH who delivered a live-born child from 2002 to 2014 and WGP, matched by origin, age, year and parity, was carried out. We compared risk factors during pregnancy and estimated risk of pregnancy- and birth-related complications using multivariate logistic regression. A total of 2334 pregnancies in 304 WLWH and 1945 WGP were included in the study. WLWH had more risk factors present than WGP during pregnancy: previous caesarean section (CS) (24.7% versus 16.3%, respectively; P = 0.0001), smoking (14.2% versus 7.5%, respectively; P = 0.0001) and previous perinatal/neonatal death (2.3% versus 0.9%, respectively; P = 0.03). We found no difference between groups regarding gestational diabetes, hypertensive disorders, low birth weights or premature delivery. More children of WLWH had intrauterine growth retardation (IUGR) [adjusted odds ratio (aOR) 1.9; 95% confidence interval (CI) 1.1-3.2; P = 0.02]. Median gestational age and birth weight were lower in children born to WLWH. WLWH had a higher risk of emergency CS (EmCS) (aOR 1.6; 95% CI 1.2-2.1; P = 0.0005) and postpartum haemorrhage (aOR 1.4; 95% CI 1.0-1.9; P = 0.02) but not infection, amniotomy, failure to progress, low activity-pulse-grimace-appearance-respiration (APGAR) score or signs of asphyxia. WLWH had more risk factors present during pregnancy, similar risks of most pregnancy- and birth-related complications but a higher risk of postpartum haemorrhage and EmCS compared with WGP. Children born to WLWH had lower median birth weights and gestational ages and were at higher risk of IUGR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-95Informations de copyright
© 2019 British HIV Association.
Références
Fowler MG, Flynn P, Aizire J. What is new in perinatal HIV prevention? Curr Opin Pediatr 2018; 30: 144-151.
Givens M, Dotters-Katz SK, Stringer E, Rahangdale L, Kuller JA. Minimizing the risk of perinatal human immunodeficiency virus transmission. Obstet Gynecol Surv 2018; 73: 423-432.
Townsend CL, Byrne L, Cortina-Borja M et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS 2014; 28: 1049-1057.
Legardy-Williams JK, Jamieson DJ, Read JS. Prevention of mother-to-child transmission of HIV-1: the role of cesarean delivery. Clin Perinatol 2010; 37: 777-785, ix.
Fiore S, Newell ML, Thorne C. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 2004; 18: 933-938.
Reitter A, Stucker AU, Linde R et al. Pregnancy complications in HIV-positive women: 11-year data from the Frankfurt HIV Cohort. HIV Med 2014; 15: 525-536.
Sebitloane HM, Moodley D. The impact of highly active antiretroviral therapy on obstetric conditions: a review. Eur J Obstet Gynecol Reprod Biol 2017; 210: 126-131.
Calvert C, Ronsmans C. HIV and the risk of direct obstetric complications: a systematic review and meta-analysis. PLoS ONE 2013; 8: e74848.
Briand N, Jasseron C, Sibiude J et al. Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000-2010. Am J Obstet Gynecol 2013; 209: 335.e1-335.e12.
Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005; 19(4): CD005479.
Boer K, Nellen JF, Patel D et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG 2007; 114: 148-155.
Aebi-Popp K, Mulcahy F, Glass TR et al. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. J Acquir Immune Defic Syndr 2013; 64: 58-65.
Boyajian T, Shah PS, Murphy KE. Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. J Obstet Gynaecol Can 2012; 34: 136-141.
Canlorbe G, Matheron S, Mandelbrot L, Oudet B, Luton D, Azria E. Vasculoplacental complications in pregnant women with HIV infection: a case-control study. Am J Obstet Gynecol 2015; 213: 241.e1-241.e9.
Maiques V, Garcia-Tejedor A, Diago V et al. Perioperative cesarean delivery morbidity among HIV-infected women under highly active antiretroviral treatment: a case-control study. Eur J Obstet Gynecol Reprod Biol 2010; 153: 27-31.
Orbaek M, Thorsteinsson K, Helleberg M et al. Assessment of mode of delivery and predictors of emergency caesarean section among women living with HIV in a matched-pair setting with women from the general population in Denmark, 2002-2014. HIV Med 2017; 18: 736-747.
Robson SJ, Vally H, Abdel-Latif ME, Yu M, Westrupp E. Childhood health and developmental outcomes after cesarean birth in an Australian cohort. Pediatrics 2015; 136: e1285-e1293.
Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. Transl Res 2017; 183: 41-56.
Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42: 81-92.
Gonzalez-Tome MI, Ramos Amador JT, Guillen S et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med 2008; 9: 868-874.
Jensen DM, Molsted-Pedersen L, Beck-Nielsen H, Westergaard JG, Ovesen P, Damm P. Screening for gestational diabetes mellitus by a model based on risk indicators: a prospective study. Am J Obstet Gynecol 2003; 189: 1383-1388.
Adams JW, Watts DH, Phelps BR. A systematic review of the effect of HIV infection and antiretroviral therapy on the risk of pre-eclampsia. Int J Gynaecol Obstet 2016; 133: 17-21.
Mesfin YM, Kibret KT, Taye A. Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis. Reprod Health 2016; 13: 30.
Ackerman W, Kwiek JJ. Role of the placenta in adverse perinatal outcomes among HIV-1 seropositive women. J Nippon Med Sch 2013; 80: 90-94.
Ewing AC, Datwani HM, Flowers LM, Ellington SR, Jamieson DJ, Kourtis AP. Trends in hospitalizations of pregnant HIV-infected women in the United States: 2004 through 2011. Am J Obstet Gynecol 2016; 215: 499.e1-499.e8.
Aliyu MH, Weldeselasse H, August EM, Keith LG, Salihu HM. Cigarette smoking and fetal morbidity outcomes in a large cohort of HIV-infected mothers. Nicotine Tob Res 2013; 15: 177-184.
Werler MM, Pober BR, Holmes LB. Smoking and pregnancy. Teratology 1985; 32: 473-481.
Lewis AJ, Austin E, Galbally M. Prenatal maternal mental health and fetal growth restriction: a systematic review. J Dev Orig Health Dis 2016; 7: 416-428.
Higgins S. Smoking in pregnancy. Curr Opin Obstet Gynecol 2002; 14: 145-151.
Mofenson LM. Antiretroviral therapy and adverse pregnancy outcome: the elephant in the room? J Infect Dis 2016; 213: 1051-1054.
Fiore S, Newell ML, Trabattoni D et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006; 70: 143-150.
Fowler MG, Qin M, Fiscus SA et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med 2016; 375: 1726-1737.
Papp E, Mohammadi H, Loutfy MR et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis 2015; 211: 10-18.
Lopez M, Palacio M, Gonce A et al. Risk of intrauterine growth restriction among HIV-infected pregnant women: a cohort study. Eur J Clin Microbiol Infect Dis 2015; 34: 223-230.
D'Souza R, Arulkumaran S. To ‘C’ or not to ‘C’? Caesarean delivery upon maternal request: a review of facts, figures and guidelines. J Perinat Med 2013; 41: 5-15.
Holm C, Langhoff-Roos J, Petersen KB, Norgaard A, Diness BR. Severe postpartum haemorrhage and mode of delivery: a retrospective cohort study. BJOG 2012; 119: 596-604.
Weeks A. The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next? BJOG 2015; 122: 202-210.
Azria E, Kane A, Tsatsaris V, Schmitz T, Launay O, Goffinet F. Term labor management and outcomes in treated HIV-infected women without contraindications to vaginal delivery and matched controls. Int J Gynaecol Obstet 2010; 111: 161-164.
Floridia M, Masuelli G, Meloni A et al. Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series. BJOG 2017; 124: 1218-1223.
Cotter AM, Brookfield KF, Duthely LM, Gonzalez Quintero VH, Potter JE, O'Sullivan MJ. Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy. Am J Obstet Gynecol 2012; 207: 482.e1-482.e5.
Thygesen LC, Ersboll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol 2014; 29: 551-558.